［1］Digklia A.Advanced gastric cancer:Current treatment landscape and future perspectives［J］.World J Gastroenterol,2016,22(8):2403-2414.
［2］Chen W,Zheng R,Baade PD,et al.Cancer statistics in China,2015［J］.CA Cancer J Clin,2016,66(2):115-132.
［3］Kim HS,Kim JH,Kim JW,et al.Chemotherapy in elderly patients with gastric cancer［J］.J Cancer,2016,7(1):88-94.
［4］Farran B,Müller S,Montenegro RC.Gastric cancer managment:Kinases as a target therapy［J］.Clin Exp Pharmacol Physiol,2017,44(6):613-622.
［5］Bastid J.EMT in carcinoma progression and dissemination:Facts,unanswered questions,and clinicalconsiderations［J］.Cancer Metastasis Rev,2012,31(1-2):277-283.
［6］Song ZY,Wu YY,Yang JB,et al.Progress in the treatment of advanced gastric cancer［J］.Tumour Biol,2017,39(7):1-7.
［7］Toh U,Fujii T,Mishima M,et al.Conventional chemotherapy combined with the repetitive immune cell transfer for patients with refractory advanced gastric cancer［J］.Gan To Kagaku Ryoho,2007,34(12):1931-1933.
［8］Shi L,Zhou Q,Wu J,et al.Efficacy of adjuvant immunotherapy with cytokine-induced killer cells in patients with locally advanced gastric cancer［J］.Cancer Immunol Immunother,2012,61(12):2251-2259.
［9］Sasada T,Kimura M,Yoshida Y,et al.CD4+ CD25+ regulatory T cells in patients with gastro- intestinal malignancies:Possible involvemen to fregulatory T cells in disease progression［J］.Cancer,2003,98(5):1089-1099.
［10］Chen XL,Cao XD,Kang AJ,et al.In situ expression and significance of B7 costimulatory moleculeswithin tissues of human gastric carcinoma［J］.World J Gastroenterol,2003,9(6):1370-1373.
［11］Parry RV,Chemnitz JM,Frauwirth KA,et al.CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms［J］.Molecular and Cellular Biology,2005,25(21):9543-9553.
［12］Jou E.Current and emerging therapies in unresectable and recurrent gastric cancer［J］.World J Gastroenterol,2016,22(20):4812-4823.
［13］Muro K,Chung HC,Shankaran V,et al.Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012):A multicentre,open-label,phase Ⅰb trial［J］.The Lancet Oncology,2016,17(6):717-726.
［14］Charles SF,Atsushi O,Josep T,et al.Pembrolizumab plus 5-fluorouracil ( 5-FU ) and cisplatin for first-line treatment of advanced gastric cancer［J］.J Clin Oncol,2016,34 (suppl15):4037.
［15］D'Angelo SP,Shoushtari AN,Keohan ML,et al.Combined KIT and CTLA-4 blockade in patients with refractory GIST and other advanced sarcomas:A phase Ib study of dasatinib plus ipilimumab［J］.Clin Cancer Res,2017,23(12):2972-2980.
［16］Fehon RG,Mc Clatchey AI,Betscher A.Organizing the cell cortex:The role of ERM proteins［J］.Nat Rev Mol Cell Biol,2010,11(4):276-287.
［17］Gao Zuowen,Zheng Jie,Lou Jinshu,et al.Analysis of clinical efficacy and prognosis of DC-CIK cellular immunotherapy in with gastric cancer［J］.Chinese Journal of Cancer Biotherapy,2017,24(2):174-179.［高作文,郑劼,娄金书,等.DC-CIK细胞免疫治疗胃癌的临床疗效及预后分析［J］.中国肿瘤生物治疗杂志,2017,24(2):174-179.］
［18］Lamers CH,Sleijfer S,Vulto AG.Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX:First clinical experience［J］.J Clin Oncol,2006,24(13):20-22.
［19］Song Y,Tong C,Wang Y,et al.Effective and persistent antitumor activity of HER2-directed CAR-T cells against gastric cancer cells in vitro and xenotransplanted tumors in vivo［J］.Protein Cell,2017,3(241-252):1-12.
［20］He LF,Yang KH,Sun N,et al.Meta analysis of pre-operationl IL-2 treatment for advanced gastric cancer［J］.Chin J Cancer Biother,2010,17(1):95-98.［贺岭风,杨克虎,孙宁,等.进展期胃癌术前应用IL-2治疗疗效的Meta分析［J］.中国肿瘤生物治疗杂志,2010,17(1):95-98.］
［21］Fewkes NM.Novel gamma-chain cytokines as candidate immune modulators in immune therapies for cancer［J］.Cancer Journal (Sudbury,Mass),2010,16(4):392-398.
［22］Wang XM,Shi RY,Jiang H.Effect of thymus V-peptide combined with BCG on immunological function in patients with gastric cancer［J］.Modern Journal of Integrated Traditional Chinese and Western Medicine,2014,23(27):3021-3023.［王学敏,石荣亚,姜华.胸腺五肽联合卡介苗治疗对胃癌患者免疫功能的影响［J］.现代中西医结合杂志,2014,23(27):3021-3023.］
［23］Ren J,Di L,Song G,et al.Selections of appropriate regimen of high-dose chemotherapy combined with adoptive cellular therapy with dendritic and cytokine-induced killer cells improved progression-free and overall survival in patients with metastatic breast cancer:Reargument of such contentious therapeutic preferences［J］.Clin Transl Oncol,2013,15(10):780-788.
［24］Ghansah T,Vohra N,Kinney K,et al.Dendritic cell immunotherapy combined with gemcitabine chemotherapy enhances survival in a murine model of pancreatic carcinoma ［J］.Cancer Immunol Immunother,2013,62(6):1083-1091.
［25］ Bang YJ,Van Cutsem E,Feyereislova A,et al.Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA):A phase 3,open-label,randomised controlled trial［J］.Lancet (London,England),2010,376(9742):687-697.
［26］ Harada S,Yanagisawa M,Kaneko S,et al.Superior antitumor activity of trastuzumab combined with capecitabine plus oxaliplatin in a human epidermal growth factor receptor 2-positive human gastric cancer xenograft model［J］.Molecular and Clinical Oncology,2015,3(5):987-994.
［27］Sullivan LA,Brekken RA.The VEGF family in cancer and antibody-based strategies fortheir inhibition［J］.MAbs,2010,2(2):165-175.
［28］Ohtsu A,Shah MA,Van Cutsem E,et al.Bevacizumab in combination with chemotherapy as frst-line therapy inadvanced gastric cancer:A randomized,double-blind,placebo-controlledphase III study［J］.J Clin Oncol,2011,29(30):3968-3976.
［29］ Wilke H,Mum K,Van Cutsem E,et al.Ramueirumab plus paclitaxel versusplacebo plus paelitaxel in patients with previouslytreated advancedgastric or gastro-oesophageal junction adeuocarcinoma(RAINBOW)：A double-blind，randomised phase 3trial［J］．Lancet Oncol,2014,15(11):1224-1235.
［30］Liguigli W,TomaseHo G,Toppo L,et al.Ramueirumab for metastaticgastric or gastroesophageal junction cancer:Results and implications ofthe REGARD trial［J］．Future Onco,2014,10(9):1549-1557.
［31］Wang Y,Wang C,Xiao H,et al.Adjuvant treatment combining cellular immunotherapy with chemotherapy improves the clinical outcome of patients with stage II/III gastric cancer［J］.Cancer Medicine,2017,6(1):45-53.
［32］Mu Y,Zhou CH,Chen SF,et al.Effectiveness and safety of chemotherapy combined with cytokine-induced killer cell /dendritic cell-cytokine-induced killer cell therapy for treatment of gastriccancer in China:A systematic review and meta-analysis［J］.Cytotherapy,2016,18(9):1162-1177.
［33］Liang QT.Effect of interferon in chemotherapy of ECF regimen in advanced gastric cancer［J］.J Henan Univ Sci Tech(Med Sci),2010,28(2):106-107.［梁群涛.干扰素对晚期胃癌ECF方案化疗的影响［J］.河南科技大学学报(医学版),2010,28(2):106-107.］
［34］Xu FJ,Han SL,Xu YC.Effect of postoperative adjuvant immunotherapy for stage Ⅲ gastric cancer［J］.Chin J Clin Oncol Rehabil,2003,10(1):53-56.［徐法杰,韩少良,徐勇超.Ⅲ期胃癌术后辅助免疫化疗的疗效观察［J］.中国肿瘤临床与康复,2003,10(1):53-56.］
［35］Tian S,Zou XP.Effect of thymosinα1 combined with chemotherapy on immune function in patients with advanced gastric cancer and quality of life［J］.China Pharmacy,2015,26(29):4115-4117.
［田升,邹晓平.胸腺肽α1联合化疗对晚期胃癌患者免疫功能与生存质量的影响［J］.中国药房,2015,26(29):4115-4117.］